It’s time for a BSB subscribers Q&A!

We haven’t done a mailbag for a while as things have been pretty hectic, but the end of a week is often a good time to consider this.

Here we take another look at the dismal, if very slowly evolving, SCLC landscape… there are some disturbances in the force here as well as some good and bad news to ponder.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers